Stay updated on Erdafitinib Intravesical for Bladder Cancer Clinical Trial
Sign up to get notified when there's something new on the Erdafitinib Intravesical for Bladder Cancer Clinical Trial page.

Latest updates to the Erdafitinib Intravesical for Bladder Cancer Clinical Trial page
- Check4 days agoChange DetectedA site-wide NIH notice about the terminology transition appears above the unavailable study record, and the site revision label changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedThe site revision label in the page footer changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check31 days agoChange DetectedThe study page now shows a 403 Forbidden error page, replacing the usual study record content and navigation.SummaryDifference19%

- Check38 days agoChange DetectedRevision tag on the Study Details page updated from v3.6.6 to v3.7.0. This change indicates a metadata maintenance update rather than a modification to the study content.SummaryDifference0.0%

- Check52 days agoChange DetectedRevision history now shows new August 2026 entries and Revision: v3.6.6. The older July 2026 entries and Revision: v3.6.5 are no longer listed.SummaryDifference0.2%

- Check59 days agoChange DetectedAdded the line 2023 ( U.S. NIH Grant/Contract ) in the study's funding information. This identifies the NIH as a funder for the year 2023, providing transparency about support for the trial.SummaryDifference0.0%

Stay in the know with updates to Erdafitinib Intravesical for Bladder Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Erdafitinib Intravesical for Bladder Cancer Clinical Trial page.